Key Takeaways:
Regencell Bioscience Holdings Limited faces a securities fraud class-action lawsuit after a U.S. Department of Justice probe into its stock trading sent shares down 18.56 percent.
"When companies fail to disclose material information, shareholders may suffer significant losses," stated Joseph E. Levi of Levi & Korsinsky, one of several firms that filed suit.
The lawsuit alleges that during the class period from October 28, 2024, to October 31, 2025, Regencell failed to disclose its vulnerability to market manipulation. On October 31, 2025, the company revealed a DOJ subpoena, causing the stock to fall $3.09 per share to $13.56.
The legal action exposes investors to further risk and follows a period of extreme volatility where shares surged from below $0.30 to $78.00 with no revenue. The deadline for investors to move for lead plaintiff is June 23, 2026.
According to the complaint, Regencell's management attributed the stock's wild fluctuations to benign factors like short squeezes rather than disclosing the underlying risks. The stock's ascent, which gave the 12-employee company a market capitalization greater than 20 of the 261 companies in the Nasdaq Biotechnology Index, occurred without any approved products or significant revenue.
The disclosure of the DOJ investigation and the subsequent lawsuits crystallize the potential harm to investors who purchased shares at what the lawsuit calls artificially inflated prices. The company has acknowledged it may be required to pay fines or penalties related to the investigation.
The lawsuits signal a period of heightened legal and financial risk for Regencell, potentially impacting its stock valuation for the foreseeable future. Investors will be watching for court rulings and further details from the ongoing DOJ investigation.
This article is for informational purposes only and does not constitute investment advice.
